GlassScriptPhysician profile
Michael W Wolff
NPI 1376508697
$2,037.19
in general payments reported to CMS, 2019-2025
22 companies · $813 in 2025
The $813 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $93.86 · 2021: $72.92 · 2022: $88.30 · 2023: $144 · 2024: $79.67 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $641 · Food and Beverage: $374 · Education: $21.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $641.38 |
| Food and Beverage | $374.41 |
| Education | $21.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $641.38 | 2025 | Optablate |
| Amgen INC. | $268.89 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $137.17 | 2025 | |
| Fidia Pharma USA INC. | $136.67 | 2019-2023 | Hymovis |
| Abbott Laboratories | $125.83 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $111.41 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.95 | 2019-2020 | |
| Arteriocyte Medical Systems, INC. | $69.07 | 2019 | |
| Collegium Pharmaceutical, INC. | $67.63 | 2019-2023 | Xtampza |
| Avanos Medical | $64.23 | 2023-2024 | Trivisc Sodium Hyaluronate, Genvisc 850 Sodium Hyaluronate |
| Bioventus LLC | $54.76 | 2019-2025 | Xcell |
| Novartis Pharmaceuticals Corporation | $39.28 | 2019 | |
| Nevro Corp. | $32.88 | 2023 | Senza |
| Allergan, INC. | $32.80 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $31.58 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $27.45 | 2023 | Sprint Pns System |
| Abbvie INC. | $26.35 | 2022 | |
| Daiichi Sankyo INC. | $23.05 | 2019 | |
| Otto Bock Healthcare LP | $21.47 | 2024 | |
| Orthogenrx INC. | $19.24 | 2019 | |
| Depuy Synthes Sales INC. | $16.60 | 2024 | Monovisc, Orthovisc |
| Sanofi-Aventis U.S. LLC | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wolff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.